These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26851042)

  • 21. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
    Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
    Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic accuracy of preoperative urinary smear test in patients with bladder urothelial carcinoma in a high-volume center.
    Restrepo-Gonzalez JA; Garcia-Perdomo HA; Varela R
    Arch Esp Urol; 2014 Apr; 67(3):243-8. PubMed ID: 24840589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens.
    Cai T; Tiscione D; Verze P; Pomara G; Racioppi M; Nesi G; Barbareschi M; Brausi M; Gacci M; Luciani LG; Liguori G; Gontero P; Campodonico F; Simonato A; Boddi V; Di Stasi SM; Colombo R; Serretta V; Carmignani G; Malossini G; Altieri V; Carini M; Terrone C; Bassi P; Montorsi F; Ficarra V; Selli C; Mirone V; Bartoletti R
    Urology; 2014 Nov; 84(5):1141-6. PubMed ID: 25239253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder.
    D'Andrea D; Moschini M; Soria F; Gust KM; Briganti A; Karakiewicz PI; Rouprêt M; Shariat SF
    Anticancer Res; 2017 Oct; 37(10):5747-5753. PubMed ID: 28982896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?
    Gontero P; Gillo A; Fiorito C; Oderda M; Pacchioni D; Casetta G; Peraldo F; Zitella A; Tizzani A; Ricceri F
    Urol Int; 2014; 92(2):136-42. PubMed ID: 24080613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
    Liu B; Miyake H; Nishikawa M; Fujisawa M
    Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Lee A; Lee HJ; Huang HH; Ho H; Chen K
    Int J Urol; 2019 Apr; 26(4):481-486. PubMed ID: 30834632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
    Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between urine cytology results on the day after overnight continuous saline irrigation following transurethral resection of bladder tumor and bladder tumor recurrence.
    Kim DH; Choi MS; Choi JH; Lee C; Jeh SU; Kam SC; Hwa JS; Hyun JS; Choi SM
    Investig Clin Urol; 2024 May; 65(3):279-285. PubMed ID: 38714518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute.
    Miyake M; Gotoh D; Shimada K; Tatsumi Y; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Konishi N; Fujimoto K
    Int J Urol; 2015 Jun; 22(6):541-7. PubMed ID: 25857336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history of positive urinary cytology after radical cystectomy.
    Raj GV; Bochner BH; Serio AM; Vickers A; Donat SM; Herr H; Lin O; Dalbagni G
    J Urol; 2006 Nov; 176(5):2000-5; discussion 2005. PubMed ID: 17070236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
    Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
    Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
    Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
    Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
    Sooriakumaran P; Chiocchia V; Dutton S; Pai A; Ayres BE; Le Roux P; Swinn M; Bailey M; Perry MJ; Issa R
    Urol Int; 2016; 96(1):83-90. PubMed ID: 26279059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.